John Sappington MD

Psychiatry•Rutherfordton, NC

Addiction, Child & Adolescent Psychiatry, Pain Medicine, Psychopharmacology

Board Certified in Addiction Medicine

Join to View Full Profile

356 Charlotte RdRutherfordton, NC 28139
Phone+1 828-287-7945

Education & Training

University of Tennessee/Saint FrancisFellowship, Addiction Medicine, 2016 - 2017
Duke School of MedicineIHC, Mindfulenss. Accupuncure , 2014 - 2015
Detroit Medical Center/Wayne State UniversityFellowship, Addiction Psychiatry, 2006 - 2007
Rhode Island Hospital/Brown University HealthFellowship, Child and Adolescent Psychiatry, 1995 - 1995
NYU Grossman School of MedicineResidency, Psychiatry, 1993 - 1994
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 1990 - 1992
McGovern Medical School at UTHealthClass of 1989
Texas A & M UniversityB.S., Biology

Certifications & Licensure

CO State Medical License 2018 - Present
RI State Medical License 1995 - 2020
NC State Medical License 2018 - 2019

Awards, Honors, & Recognition

American Board of Addiction Medicine Board Certified
Addiction Psychiatry Fellow Addiction Research Institute, 2006
Acting Addiction Psychiatry Fellow American Society of Addiction Medicine, 1994

Clinical Trials

Naltrexone for Heavy Drinking in Young Adults Start of enrollment: 2008 Feb 01
Completed
Phase 4
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Start of enrollment: 2007 Sep 01
Completed
Phase 3
Combination of Naltrexone and Baclofen for Alcohol Dependence:A Pilot Study. Start of enrollment: 2007 Jul 01
Completed
Phase 1
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain Start of enrollment: 2010 Dec 01
Completed
Phase 3
Naltrexone and Memantine Effects on Alcohol Drinking Behaviors Start of enrollment: 2012 Jan 01
Completed
Phase 2
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Start of enrollment: 2014 Jun 27
Completed
Phase 4
Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Start of enrollment: 2014 Jan 29
Completed
Phase 4
Ketamine for Depression and Suicide Risk Start of enrollment: 2014 Sep 01
Completed
Phase 2
Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting Start of enrollment: 2014 Nov 01
Unknown status
Phase 3
A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects Start of enrollment: 2015 Feb 01
Completed
Phase 3
Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery Start of enrollment: 2016 Feb 01
Withdrawn
Phase 4
Evaluation of Naltrexone as a Treatment for Self-injurious Behavior Start of enrollment: 2014 Feb 22
Withdrawn
Phase 4
Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Start of enrollment: 2016 Jun 01
Completed
Phase 4
Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) Start of enrollment: 2016 Sep 01
Completed
Phase 1
Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients Start of enrollment: 2016 Oct 14
Completed
Phase 2
Low Dose Naltrexone for Chronic Pain From Arthritis Start of enrollment: 2018 May 01
Completed
Phase 2
Ketamine as an Adjunctive Therapy for Major Depression Start of enrollment: 2017 Sep 07
Completed
Phase 1
Addiction Among Mental Health Professionals Start of enrollment: 2018 Feb 01
Unknown status
Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder Start of enrollment: 2016 May 01
Completed
Phase 2
Join now to see all